Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer

PURPOSE: We examined the safety and efficacy of the combination of S-1 and biweekly docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). METHODS: Patients with previously treated advanced NSCLC were eligible if they had a performance status of 2 or less, were 80...

Descripción completa

Detalles Bibliográficos
Autores principales: Oki, Yasunari, Hirose, Takashi, Yamaoka, Toshimitsu, Kusumoto, Sojiro, Shirai, Takao, Sugiyama, Tomohide, Okuda, Kentaro, Nakashima, Masanao, Murata, Yasunori, Ohmori, Tohru, Adachi, Mitsuru
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064900/
https://www.ncbi.nlm.nih.gov/pubmed/20556612
http://dx.doi.org/10.1007/s00280-010-1382-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064900/
https://www.ncbi.nlm.nih.gov/pubmed/20556612
http://dx.doi.org/10.1007/s00280-010-1382-1

Ejemplares similares